Drug
Flixebrutinib clinical trials
Also written TL-895.
Keep track of what changes. Save the flixebrutinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Telios Pharma, Inc. (4) · Kartos Therapeutics, Inc. (2) · Merck KGaA, Darmstadt, Germany (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses flixebrutinib is read from its arms, and is right about nine times in ten.
Testing it · 7
- Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisRecruitingPhase 2Telios Pharma, Inc.NCT04655118Written as TL-895
- Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibRecruitingPhase 1/2Telios Pharma, Inc.NCT05280509Written as TL-895
- KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFRecruitingPhase 1/2Kartos Therapeutics, Inc.NCT04640532Written as TL-895
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisRecruitingPhase 2Kartos Therapeutics, Inc.NCT04878003Written as TL-895
- TL-895 and KRT-232 Study in Acute Myeloid LeukemiaActive, not recruitingPhase 1/2Telios Pharma, Inc.NCT04669067Written as TL-895
- A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With CancerCompletedPhase 1Telios Pharma, Inc.NCT04419623Written as TL-895
- M7583 Relative Bioavailability of Tablet Compared to Powder-in-capsuleCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03297983Written as M7583
Given in every arm · 1 — flixebrutinib is usual care beside what is tested
Codes
What other systems call flixebrutinib · ClinicalTrials.gg INT018638
- UNII (FDA) Z0X30O5NT8FLIXEBRUTINIBOne source FDA
- NCI Thesaurus C129710FlixebrutinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z0X30O5NT8 | FLIXEBRUTINIB | One source FDA |
| NCI Thesaurus | C129710 | Flixebrutinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.